KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abbott Laboratories (ABT) Cash from Operations (2016 - 2025)

Abbott Laboratories' Cash from Operations history spans 17 years, with the latest figure at 3315000000.0 for Q4 2025.

  • For Q4 2025, Cash from Operations rose 15.59% year-over-year to 3315000000.0; the TTM value through Dec 2025 reached 9566000000.0, up 11.78%, while the annual FY2025 figure was 9566000000.0, 11.78% up from the prior year.
  • Cash from Operations for Q4 2025 was 3315000000.0 at Abbott Laboratories, up from 2787000000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 3315000000.0 in Q4 2025 and bottomed at 1025000000.0 in Q1 2024.
  • The 5-year median for Cash from Operations is 2368000000.0 (2022), against an average of 2274950000.0.
  • The largest annual shift saw Cash from Operations skyrocketed 268.81% in 2021 before it tumbled 50.08% in 2023.
  • A 5-year view of Cash from Operations shows it stood at 3067000000.0 in 2021, then dropped by 24.16% to 2326000000.0 in 2022, then skyrocketed by 30.61% to 3038000000.0 in 2023, then fell by 5.6% to 2868000000.0 in 2024, then increased by 15.59% to 3315000000.0 in 2025.
  • Per Business Quant, the three most recent readings for ABT's Cash from Operations are 3315000000.0 (Q4 2025), 2787000000.0 (Q3 2025), and 2047000000.0 (Q2 2025).